Evidence map›Paper›PMID 40595642›Full record

ArticleNature communications2025

Caffeine enhances antitumor T-cell activity by suppressing kynurenine pathway in colorectal cancer.

Yuechen Liu, Zhengyu Liu, Yating Hu, Yunyan Ling, Shunjie Qing, Yang Liu, Yizhi Zhan, Zhiyong Shen, Yuan Fang, Haijun Deng

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. International journal of nanomedicine · 2026
    Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuechen Liu *Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China.ORCID http://orcid.org/0000-0003-3001-115X
Zhengyu Liu *Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China.
Yating Hu *Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China.
Yunyan Ling *Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China.
Shunjie QingDepartment of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China.
Yang LiuDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China.
Yizhi ZhanDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China.ORCID http://orcid.org/0000-0002-5079-6129
Zhiyong ShenDepartment of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China. szy2728@163.com.ORCID http://orcid.org/0000-0003-4950-2434
Yuan FangDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China. fangyuan1313@163.com.ORCID http://orcid.org/0000-0003-0483-2237
Haijun DengDepartment of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China. navyd999@163.com.ORCID http://orcid.org/0000-0003-4632-2702

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81972631,82273039,82472887National Natural Science Foundation of China (National Science Foundation of China) 82073063National Natural Science Foundation of China (National Science Foundation of China) 82103595Natural Science Foundation of Guangdong Province (Guangdong Natural Science Foundation) 2021A1515010989,2023A1515010274Natural Science Foundation of Guangdong Province (Guangdong Natural Science Foundation) 2022A1515010298,2023A1515010980Natural Science Foundation of Guangdong Province (Guangdong Natural Science Foundation) 2023A1515011789, 2025A1515011911
6 · The paper itself

Abstract

Colorectal cancer (CRC) is a leading global health issue, ranking third in incidence and second in cancer mortality. Immunotherapy, effective mainly in mismatch repair-deficient CRC, may benefit from dietary interventions. This study investigates caffeine's potential to boost programmed death-1 (PD-1) immunotherapy efficacy in CRC, revealing that caffeine significantly reduces tumor growth, extends survival, and enhances CD8

Indexed as

CaffeineCD8-Positive T-LymphocytesColorectal NeoplasmsKynurenineAnimalsCell Line, TumorFemaleHumansImmunotherapyIndoleamine-Pyrrole 2,3,-DioxygenaseMaleMiceMice, Inbred C57BLProgrammed Cell Death 1 ReceptorSignal TransductionXenograft Model Antitumor AssaysCaffeineIndoleamine-Pyrrole 2,3,-DioxygenaseKynurenineProgrammed Cell Death 1 Receptor

Identifiers

PMID40595642
PMCPMC12216989

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.